Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0004462 |
Description |
|
Trait category |
Cardiovascular measurement
|
Mapped term(s) | NCIt:C83502 |
Polygenic Score (PGS) ID | PGS Name | PGS Publication (PGP) ID | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | PGS Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000735 | PRS_PR | PGP000144 Tadros R et al. Eur Heart J (2019) |
PR interval | PR interval | 44 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000735/ScoringFiles/PGS000735.txt.gz |
PGS Performance Metric ID (PPM ID) |
Evaluated Score |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM001750 | PGS000735 (PRS_PR) |
PSS000906 | PGP000144 Tadros R et al. Eur Heart J (2019) |
Reported Trait: Baseline PR in non SCN5A mutation carriers | — | — | Correlation coefficent (r): 0.23 | — | — |
PPM001752 | PGS000735 (PRS_PR) |
PSS000906 | PGP000144 Tadros R et al. Eur Heart J (2019) |
Reported Trait: PR slope in non SCN5A mutation carriers | β: 0.16 (0.08) | — | Correlation coefficient (r): 0.09 | — | — |
PPM001754 | PGS000735 (PRS_PR) |
PSS000904 | PGP000144 Tadros R et al. Eur Heart J (2019) |
Reported Trait: PR slope | β: 0.22 (0.08) | — | — | — | — |
PPM001759 | PGS000735 (PRS_PR) |
PSS000905 | PGP000144 Tadros R et al. Eur Heart J (2019) |
Reported Trait: Ajmaline-induced Type I Brugada syndrome electrocardiogram | OR: 1.017 [1.013, 1.022] | — | — | — | — |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000904 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.12 | — | 1,257 individuals | — | European | — | Amsterdam | — |
PSS000905 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.15 | — | 1,185 individuals | — | European | — | Amsterdam | — |
PSS000906 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.13 | — | 1,193 individuals | — | European | — | Amsterdam | — |